Literature DB >> 17220171

Stat5 constitutive activation rescues defects in spinal muscular atrophy.

Chen-Hung Ting1, Chiao-Wei Lin, Shin-Lan Wen, Hsiu-Mei Hsieh-Li, Hung Li.   

Abstract

Proximal spinal muscular atrophy (SMA) is a motor neuron degeneration disorder for which there is currently no effective treatment. Here, we report three compounds (sodium vanadate, trichostatin A and aclarubicin) that effectively enhance SMN2 expression by inducing Stat5 activation in SMA-like mouse embryonic fibroblasts and human SMN2-transfected NSC34 cells. We found that Stat5 activation enhanced SMN2 promoter activity with increase in both full-length and deletion exon 7 SMN transcripts in SMN2-NSC34 cells. Knockdown of Stat5 expression disrupted the effects of sodium vanadate on SMN2 activation but did not influence SMN2 splicing, suggesting that Stat5 signaling is involved in SMN2 transcriptional regulation. In addition, constitutive activation of Stat5 mutant (Stat5A1*6) profoundly increased the number of nuclear gems in SMA-patient lymphocytes and reduced SMA-like motor neuron axon outgrowth defects. These results demonstrate that Stat5 signaling could be a possible pharmacological target for treating SMA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220171     DOI: 10.1093/hmg/ddl482

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  19 in total

Review 1.  Spinal muscular atrophy: an update on therapeutic progress.

Authors:  Joonbae Seo; Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Biochim Biophys Acta       Date:  2013-08-27

Review 2.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

3.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

4.  Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway.

Authors:  Faraz Farooq; Francisco Abadía Molina; Jeremiah Hadwen; Duncan MacKenzie; Luke Witherspoon; Matthew Osmond; Martin Holcik; Alex MacKenzie
Journal:  J Clin Invest       Date:  2011-07-25       Impact factor: 14.808

5.  Electrophysiological properties of motor neurons in a mouse model of severe spinal muscular atrophy: in vitro versus in vivo development.

Authors:  Hongmei Zhang; Natallia Robinson; Chiayen Wu; Wenlan Wang; Melissa A Harrington
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

Review 6.  SMN-inducing compounds for the treatment of spinal muscular atrophy.

Authors:  Monique A Lorson; Christian L Lorson
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

Review 7.  Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein.

Authors:  Ryan S Anderton; Bruno P Meloni; Frank L Mastaglia; Sherif Boulos
Journal:  Mol Neurobiol       Date:  2013-01-13       Impact factor: 5.590

8.  Embryonic motor axon development in the severe SMA mouse.

Authors:  Vicki L McGovern; Tatiana O Gavrilina; Christine E Beattie; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2008-07-03       Impact factor: 6.150

9.  Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice.

Authors:  Li-Kai Tsai; Ming-Shiun Tsai; Chen-Hung Ting; Hung Li
Journal:  J Mol Med (Berl)       Date:  2008-07-23       Impact factor: 4.599

Review 10.  Splicing of the Survival Motor Neuron genes and implications for treatment of SMA

Authors:  Thomas W Bebee; Jordan T Gladman; Dawn S Chandler
Journal:  Front Biosci (Landmark Ed)       Date:  2010-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.